Trends in in-hospital mortality by month during the pre-intervention period (Phase 1) and interventional period (Phases 2–4). by Naoya Itoh (6029276)

Trends in the days of cefalexin therapy per 100 patients, by month, during Phases 1 to 4. by Naoya Itoh (6029276)

Trends in the days of quinolone therapy per 100 patients, by month, during Phases 1 to 4. by Naoya Itoh (6029276)

Trends in the length of hospital stay by month during the pre-intervention period (Phase 1) and interventional period (Phases 2–4). by Naoya Itoh (6029276)

Trends in the days of macrolides therapy per 100 patients, by month, during Phases 1 to 4. by Naoya Itoh (6029276)

Trends in the days of amoxicillin and amoxicillin-clavulanate therapy per 100 patients, by month, during Phases 1 to 4. by Naoya Itoh (6029276)

Trends in the days of third-generation cephalosporin therapy per 100 patients, by month, during Phases 1 to 4. by Naoya Itoh (6029276)

Trends in the incidence of <i>Clostridioides difficile</i> infection (CDI) per 1000 patients, by month, during the pre-intervention period (Phase 1) and interventional period (Phas... by Naoya Itoh (6029276)

Trends in the incidence of extended-spectrum β-lactamase (ESBL)- producing Enterobacteriaceae per 1000 patients, by month, during the pre-intervention period (Phase 1) and interven... by Naoya Itoh (6029276)

Trends in the incidence of methicillin-resistant <i>Staphylococcus aureus</i> (MRSA) per 1000 patients, by month, during the pre-intervention period (Phase 1) and interventional pe... by Naoya Itoh (6029276)

Trends in the incidence of penicillin-resistant <i>Streptococcus pneumoniae</i> (PRSP) per 1000 patients, by month, during the pre-intervention period (Phase 1) and interventional... by Naoya Itoh (6029276)

Trends in the incidence of resistant <i>Haemophilus influenzae</i> per 1000 patients, by month, during the pre-intervention period (Phase 1) and interventional period (Phases 2–4).... by Naoya Itoh (6029276)

Observed and predicted changes for the five metabolites significantly associated with the rs603424 SNP. by Juliette Cooke (11402543)

Principal component analyses indicates no significant separation based on the type of brain regions. by Marcell Miski (11965487)

Time-based changes in factor scores by group. by Shota Fujiwara (22410782)

Subjects:

Changes in alpha diversity in the weeks before anti-TNF-a treatment. by Katrine Carlsen (5477300)

“…The analysis found a significant association across all subjects for Shannon diversity with decreasing diversity in the lead up to the next treatment (lmer model, beta = -0.018, <i>p</i> = 0.036) and no association for observed diversity (<i>p</i>>0.1). …”

Linear regression between PCB TEQ and ∑PCB in different study areas. by Matti Viluksela (321291)

Linear regression between ∑PCB and ∑indicator PCB in different study areas. by Matti Viluksela (321291)

Mean and SDs of the significant regions. by Faran Sabeti (6166766)

Subjects:

Patients with high baseline gut richness and diversity have significantly greater decreases in diversity over time. by Molly B. El Alam (10231830)